Ivabradine, a novel medication for treatment of heart failure with reduced ejection fraction. Issue 11 (24th May 2016)

• Record Type: Journal Article
• Authors: Foster, Jenna L.; Bobadilla, Rodel V.
• Is Part Of: Journal of the American Association of Nurse Practitioners. Volume 28:Issue 11(2016)
• Page Start: 576
• Page End: 582
• Publication Date: 2016-05-24
• Subjects: Heart failure -- medications -- hospital readmission -- cardiovascular; Nurse practitioners -- Periodicals; Nursing -- Periodicals; 610.730692
• DOI: 10.1002/2327-6924.12371
• Languages: English
• ISSNs: 2327-6886

Abstract

Abstract: Purpose: To critically evaluate current literature, review pharmacology, and discuss clinical role of ivabradine for patients with heart failure (HF) with reduced ejection fraction. Data sources: A PubMed search was conducted using the search terms ivabradine and HF. All human studies analyzing the use of ivabradine in patients with HF with reduced ejection fraction and prescribing information were evaluated. Conclusions: Greater benefit was seen in the prespecified subgroup with heart rate (HR) > 70 beats per minute (bpm) in the BEAUTIFUL study. Therefore, SHIFT examined the effect of ivabradine on patients with higher resting HR, lower ejection fraction, who had been hospitalized for HF within the previous year. A significant difference was found in the composite primary endpoint of cardiovascular death and hospitalizations for worsening HF in patients with HF and left ventricular systolic dysfunction, driven primarily by reduction in hospitalizations for worsening HF. The most common adverse effect was bradycardia. Implications for practice: Ivabradine is a safe and effective medication for HR reduction to reduce hospitalizations in patients with stable, symptomatic HF (ejection fraction < 35%), in sinus rhythm, and HR > 70 bpm.